Galectin Therapeutics Inc. (NASDAQ:GALT) is set to post its quarterly earnings results before the market opens on Monday, November 6th. Analysts expect Galectin Therapeutics to post earnings of ($0.15) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Monday, August 14th. The company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same quarter last year, the firm earned ($0.20) EPS. On average, analysts expect Galectin Therapeutics to post $-0.56 EPS for the current fiscal year and $-0.61 EPS for the next fiscal year.

Galectin Therapeutics Inc. (NASDAQ:GALT) opened at 2.60 on Monday. Galectin Therapeutics Inc. has a 52 week low of $0.49 and a 52 week high of $3.68. The stock has a 50 day moving average of $2.25 and a 200-day moving average of $2.35. The firm’s market cap is $91.13 million.

A number of research firms have recently weighed in on GALT. ValuEngine downgraded Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, September 21st. Seaport Global Securities reissued a “buy” rating and set a $5.00 target price on shares of Galectin Therapeutics in a report on Friday, October 6th. Roth Capital began coverage on Galectin Therapeutics in a report on Thursday, October 19th. They set a “buy” rating and a $8.00 target price for the company. Finally, Zacks Investment Research downgraded Galectin Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $4.63.

An institutional investor recently raised its position in Galectin Therapeutics stock. Northern Trust Corp lifted its position in shares of Galectin Therapeutics Inc. (NASDAQ:GALT) by 4.4% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,097 shares of the company’s stock after buying an additional 3,176 shares during the quarter. Northern Trust Corp owned about 0.22% of Galectin Therapeutics worth $185,000 as of its most recent SEC filing. Institutional investors own 9.87% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Galectin Therapeutics Inc. (GALT) Set to Announce Earnings on Monday” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/30/galectin-therapeutics-inc-galt-set-to-announce-earnings-on-monday.html.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Earnings History for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.